



# SHUKRA

PHARMACEUTICALS LTD.

11<sup>th</sup> November, 2020

To  
The General Manager-Listing  
Corporate Relationship Department  
BSE Limited, Ground Floor,  
P.J. Towers, Dalal Street, Mumbai.

Scrip Code: 524632

Dear Sir/Madam,

**SUB: - OUTCOME OF BOARD MEETING**

With reference to above subject and in compliance with the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e. 11<sup>th</sup> November, 2020 at 04.00 p.m. and concluded at 05:35 p.m.:-

1. Considered, adopted and approved Unaudited Financial Results for the quarter and Half year ended on 30<sup>th</sup> September, 2020.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully

For Shukra Pharmaceuticals Limited

  
Arpita Shah  
Company Secretary &  
Compliance officer

Email id: [info@shukrapharmaceuticals.com](mailto:info@shukrapharmaceuticals.com) Website: [www.shukrapharmaceuticals.com](http://www.shukrapharmaceuticals.com)

**CIN : L24231GJ1993PLC019079**



# SHUKRA

## PHARMACEUTICALS LTD.

### Statement of Standalone Unaudited Financial Results for the Quarter Ended 30-09-2020

SR NO	PARTICULARS	Standalone (₹ in Lakhs)					
		Quarter Ended			Half Year		Year Ended
		30-09-2020 (Unaudited) QUARTERLY	30-06-2020 (Unaudited) QUARTERLY	30-09-2019 (Unaudited) QUARTERLY	30-09-2020 (Unaudited) HALF YEARLY	30-09-2019 (Unaudited) HALF YEARLY	31-03-2020 (Audited) YEARLY
<b>1</b>	<b>Income</b>						
	Revenue from operations - Job Charges	167.60	110.89	148.65	278.49	252.99	1,184.60
	Other income	9.91	13.95	140.00	23.86	140.00	0.97
	<b>Total income</b>	<b>177.51</b>	<b>124.84</b>	<b>288.65</b>	<b>302.35</b>	<b>392.99</b>	<b>1,185.57</b>
<b>2</b>	<b>Expenses</b>						
(a)	Cost of materials consumed	7.10	35.21	127.46	42.31	142.68	332.82
(b)	Purchases of stock-in-trade	-	-	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(24.16)	(44.14)	0.00	(68.30)	(8.04)	(25.90)
(d)	Employee benefit expense	90.85	58.02	95.72	148.87	166.89	440.03
(e)	Finance costs	0.30	0.02	-	0.32	0.07	0.21
(f)	Depreciation, depletion and amortisation expense	36.21	36.21	35.49	72.42	50.49	147.82
(f)	Other Expenses	57.99	37.65	27.50	95.64	38.15	283.61
	<b>Total expenses</b>	<b>168.28</b>	<b>122.97</b>	<b>286.17</b>	<b>291.25</b>	<b>390.24</b>	<b>1,178.59</b>
<b>3</b>	<b>Total profit before exceptional items and tax</b>	<b>9.22</b>	<b>1.87</b>	<b>2.48</b>	<b>11.09</b>	<b>2.75</b>	<b>6.98</b>
<b>4</b>	<b>Exceptional items</b>	-	-	-	-	-	10.10
<b>5</b>	<b>Total profit before tax</b>	<b>9.22</b>	<b>1.87</b>	<b>2.48</b>	<b>11.09</b>	<b>2.75</b>	<b>17.08</b>
<b>7</b>	<b>Tax expense</b>						
<b>8</b>	Current tax	-	-	-	-	-	13.52
<b>9</b>	Deferred tax	-	-	-	-	-	-
<b>10</b>	<b>Total tax expenses</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>13.52</b>
<b>11</b>	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	-	-	-	-	-	-
<b>12</b>	<b>Net Profit Loss for the period from continuing operations</b>	<b>9.22</b>	<b>1.87</b>	<b>2.48</b>	<b>11.09</b>	<b>2.75</b>	<b>3.56</b>
<b>13</b>	Profit (loss) from discontinued operations before tax	-	-	-	-	-	-
<b>14</b>	Tax expense of discontinued operations	-	-	-	-	-	-
<b>15</b>	Net profit (loss) from discontinued operation after tax	-	-	-	-	-	-
<b>16</b>	Share of profit (loss) of associates and joint ventures accounted for using equity method	-	-	-	-	-	-
<b>17</b>	<b>Total profit (loss) for period</b>	<b>9.22</b>	<b>1.87</b>	<b>2.48</b>	<b>11.09</b>	<b>2.75</b>	<b>3.56</b>
<b>18</b>	Other comprehensive income net of taxes	-	-	-	-	-	-
<b>19</b>	<b>Total Comprehensive Income for the period</b>	<b>9.22</b>	<b>1.87</b>	<b>2.48</b>	<b>11.09</b>	<b>2.75</b>	<b>3.56</b>
<b>20</b>	<b>Total profit or loss, attributable to</b>	<b>9.22</b>	<b>1.87</b>	<b>2.48</b>	<b>11.09</b>	<b>2.75</b>	<b>3.56</b>
	Profit or loss, attributable to owners of parent	-	-	-	-	-	-
	Total profit or loss, attributable to non-controlling interests	-	-	-	-	-	-
<b>21</b>	<b>Total Comprehensive income for the period attributable to</b>						
	Comprehensive income for the period attributable to owners of parent	-	-	-	-	-	-
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	-	-	-	-	-	-
<b>22</b>	<b>Details of equity share capital</b>						
	Paid-up equity share capital	156.57	156.57	156.57	156.57	156.57	156.57
	Face value of equity share capital	10.00	10.00	10.00	10.00	10.00	10.00
<b>23</b>	<b>Details of debt securities</b>						
	Paid-up debt capital	-	-	-	-	-	-
	Face value of debt securities	-	-	-	-	-	-
<b>24</b>	<b>Earnings per share</b>						
i	<b>Earnings per equity share for continuing operations</b>						
	Basic earnings (loss) per share from continuing operations	0.59	0.12	0.16	0.71	0.18	0.23
	Diluted earnings (loss) per share from continuing operations	0.59	0.12	0.16	0.71	0.18	0.23
ii	<b>Earnings per equity share for discontinued operations</b>						
	Basic earnings (loss) per share from discontinued operations	-	-	-	-	-	-
	Diluted earnings (loss) per share from discontinued operations	-	-	-	-	-	-
ii	<b>Earnings per equity share</b>						
	Basic earnings (loss) per share from continuing and discontinued operations	-	-	-	-	-	-
	Diluted earnings (loss) per share from continuing and discontinued operations	-	-	-	-	-	-
<b>25</b>	<b>Disclosure of notes on financial results</b>						

CIN : L24231GJ1993PLC019079







# SHUKRA

PHARMACEUTICALS LTD.

**NOTES:**

1. The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 11th November, 2020. The statutory auditors have carried out a limited review of the results for the quarter ended September 30, 2020 and have expressed
2. The figures for the previous period/year have been regrouped /reclassified , wherever necessary.
3. This Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 ( Ind AS ), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
4. The Disclosure is as per Regulation 33 of SEBI (Listing Obligations & Discloser Requirements) Regulations, 2015,
5. The Company is operating in single segment, so above results are for single segment only.

Date: 11-11-2020  
Place: Ahmedabad

For and on behalf of the Board of Directors  
SHUKRA PHARMACEUTICALS LIMITED

*M. Patel*  
Mleshkumar Patel (Director)  
DIN: 08316887



**CIN : L24231GJ1993PLC019079**



# SHUKRA

## PHARMACEUTICALS LTD.

Statement Of Assets and Liability		
Particulars	( ₹ In Lacs)	
	Standalone	
	As at 30th September 2020	As at 31st March 2020
	Unaudited	Audited
<b>A) Assets</b>		
<b>Non Current Assets</b>		
Property Plant and Equipement	1,891.01	1,737.91
Capital Work In Progress	166.17	166.17
Other Intengible Assets		
Intengible assets under Development		
Financial Assets		
i) Investment	18.69	5.23
ii) Loan		
iii) Other Financial Assets		
Deferred Tax Assets (net)		
Other non current Assets		
<b>Total Non Current Assets</b>	<b>2,075.88</b>	<b>1,909.31</b>
<b>Current Assets</b>		
Inventories/WIP	189.88	131.87
Financial Assets		
i) Trade Receivable	671.52	795.12
ii) Cash and Cash Equivalents	12.51	12.64
iii) Bank Balance other than (ii)above		
iv) Other Financial Assets	539.98	473.88
Other Current Assets	78.33	29.93
<b>Total Curent Assets</b>	<b>1,492.20</b>	<b>1,443.44</b>
<b>Total Assets</b>	<b>3,568.08</b>	<b>3,352.75</b>
<b>B) Equity and Liabilities</b>		
Equity Share Capital	156.57	156.57
Other Equity	1,395.64	1,384.55
<b>Total Equity</b>	<b>1,552.21</b>	<b>1,541.12</b>
<b>Non Current Liabilities</b>		
Financial Liabilities		
i) Borrowings	961.0	805.2
Defered Tax Liabilities	309.6	309.6
<b>Total Non Current Liabilities</b>	<b>1,270.68</b>	<b>1,114.81</b>
<b>Current Liabilities</b>		
Financial Liabilities		
i) Borrowings		
ii) Trade Payables	721.81	644.36
iii) Other Financial Liabilities		
Provisions	23.39	52.46
Other Current Liabilities		
<b>Total Current Liabilities</b>	<b>745.19</b>	<b>696.82</b>
<b>Total Equity and Liabilities</b>	<b>3,568.08</b>	<b>3,352.75</b>

CIN : L24231GJ1993PLC019079





# SHUKRA

PHARMACEUTICALS LTD.

## Cash flow Statement

PARTICULARS	For the Half year ended on 30-09-2020	For the year ended on 31-03-2020
<b>(A) Cash flow from operating activities</b>		
Profit/(Loss) before tax	11.09	17.08
<u>Adjustment For:</u>		
Depreciation	72.42	147.82
Interest and other finance expense	0.32	0.00
Interest Income	3.14	0.00
Excess provision for Taxation/Dividend written back	0.00	10.30
<b>Operating profit before working capital changes</b>	<b>86.97</b>	<b>175.20</b>
<b>Adjustment for increase/decrease in :</b>		
Trade payables	77.45	329.42
Short Term provisions	-29.07	-32.28
Trade receivables	123.60	-260.48
Short term loans and advances	-66.10	15.23
Other current assets	-48.40	1.71
Inventories	-58.01	-104.8
Cash generated from /(used in) operations	86.45	124.00
Direct Tax Paid	0.00	0.00
<b>Net cash flow from/ (used in) operating activities A</b>	<b>86.45</b>	<b>124.00</b>
<b>(B) Cash flows from investing activities</b>		
Purchase of fixed assets	-225.36	-322.22
Sale of fixed assets	0.10	11.00
Purchase of Investment/Increase in investment	-13.46	-0.06
Interest Received	-3.14	0.00
<b>Net cash flow from/ (used in) investing activities B</b>	<b>(241.87)</b>	<b>(311.28)</b>
<b>(C) Cash flows from financing activities</b>		
Increase / (Decrease) in Unsecured Loan	155.86	199.49
Interest and financial expense	-0.32	0.00
<b>Net cash flow from/ (used in) in financing activities C</b>	<b>155.54</b>	<b>199.49</b>
<b>Net increase/decrease in cash and cash equivalents A + B + C</b>	<b>0.13</b>	<b>12.21</b>
Cash and cash equivalents as at beginning	12.64	24.85
Cash and cash equivalents as at end	12.51	12.64
<b>Net Increase/decrease in Cash and cash equivalents</b>	<b>0.13</b>	<b>12.21</b>

CIN : L24231GJ1993PLC019079

